Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Panel Backs Approval of Pimavanserin

Big News for Advanced Parkinson’s

Washington, D.C. — Today, an FDA advisory board voted to approve Acadia Pharmaceutical’s new antipsychotic medication, pimavanserin, which will be marketed under the name Nuplazid™. Previously, there was no FDA-approved drug for the treatment of psychosis A broad medical term used to describe a loss of contact with reality that involves hallucinations and/or delusions. in Parkinson’s, and expert neurologists and psychiatrists had the option of several atypical antipsychotic medications, none of which were proven effective in Parkinson’s, or one that was proven effective but had a fairly negative safety profile, with patients requiring weekly blood tests to make sure that they were tolerating the drug well.

However, with the lack of an FDA-approved drug for Parkinson’s disease psychosis, this troubling and sometimes terrible symptom is frequently untreated or, worse yet, treated with an antipsychotic medication that is not safe for Parkinson’s patients.  Many antipsychotic drugs work by blocking dopamine A chemical messenger (neurotransmitter) that regulates movement and emotions..  Since Parkinson’s is a disease where dopamine producing neurons are lost, blocking dopamine is bad – we think that sometimes it is fatal.

The approval of a drug to treat Parkinson’s disease psychosis will mean that there is a clear option for patients.  These are powerful drugs, so there are risks associated with any antipsychotic treatment – an issue presented to the FDA’s panel by Marc Stone, MD, the FDA’s Deputy Director of Safety – and so patients and families need to be careful and talk to their neurologist about all their options.  However, with FDA approval, we can hope that most patients with Parkinson’s will have access to a drug designed just for them and for Parkinson’s.

During the public comment period, many patients spoke about the impact of psychosis on their family.  These powerful testaments – many of which were from people who had participated in the clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe. of pimavanserin – described the impact of the drug in a way that went far beyond the numbers from the trial results.  Some people told us of the total resolution of hallucinations and delusions in a spouse, parent, or grandparent from taking pimavanserin in the clinical trial and others talked about how their spouse realized that hallucinations were not real, thanks to the treatment.

David Pickar, MD, a key member of the Psychopharmacologic Drugs Advisory Committee, pointed out that he felt that this was not for Parkinson’s disease psychosis, but rather for psychosis in patients being treated for Parkinson’s disease, because every patient in the study was receiving clinically optimized medication to manage their motor symptoms.  This is an important point, but also largely an academic one – since psychosis is usually seen later in the disease, use of this drug will be almost exclusively in treated Parkinson’s.

Hopefully, this success of the process for pimavanserin will inspire others to aggressively pursue novel therapies for Parkinson’s.  We hope that this approval will lead to better outcomes for people with Parkinson’s today and that this success of the drug approval process will inspire others to pursue the next breakthrough.

Peter N. Schmidt, Ph.D., Senior Vice President, Chief Mission Officer

Dr. Schmidt can be reached at pschmidt@parkinson.org.

Tuesday, March 29, 2016
Parkinson’s Foundation Awards New Nurse Faculty Grant to Four Nurses Specializing in Parkinson’s Care
Thursday, October 11, 2018

NEW YORK & MIAMI — October 11, 2018 — The Parkinson’s Foundation announced that it has awarded its first-ever Parkinson’s Foundation Nurse Faculty Award to four nurses, totaling $30,000. The nurses, all graduates of the Edmond J.

Update on NUPLAZID — FDA finds no new or unexpected safety risks
Friday, September 21, 2018

On September 20, 2018, the U.S.

Parkinson’s Foundation Extends Bilingual National Helpline Hours
Tuesday, September 18, 2018

NEW YORK & MIAMI — September 18, 2018 — The Parkinson’s Foundation announced today that its toll-free Helpline, 1-800-4PD-INFO, will extend its hours, answering calls in English and Spanish, to help make life better for people with Parkinson’s disease (PD) and their families.

Parkinson’s Foundation Hosts Allied Team Training for Parkinson’s in Atlanta
Tuesday, September 11, 2018

NEW YORK & MIAMI—September 11, 2018—The Parkinson’s Foundation today announced the location of its signature professional education program course, Allied Team Training for Parkinson’s, ATTP®, for health care professionals treating patients with Parkinson’s disease, in Atlanta.

Parkinson’s Foundation Increases Funding to $6.2 Million to Advance Parkinson’s Research
Tuesday, August 14, 2018

NEW YORK & MIAMI — August 14, 2018 — The Parkinson’s Foundation announced today an increased investment of $6.2 million across 53 research grants to support the work of promising scientists in the field of Parkinson's disease (PD) in 2018.

PD Gladiators Merges with the Parkinson’s Foundation Expanding Reach in Greater Atlanta Parkinson’s Community
Wednesday, August 1, 2018

ATLANTA – August 1, 2018—PD Gladiators, Inc., an Atlanta-based nonprofit organization focused on combatting Parkinson’s disease (PD) with vigorous exercise, has merged with the Parkinson’s Foundation (PF), a non-profit organization whose mission is to make life better for people with PD worldwide through expert care and research.

Parkinson’s Foundation Partners with Medscape Education to Deliver Patient Education
Monday, July 30, 2018

July 30, 2018—The Parkinson’s Foundation has collaborated with Medscape Education to launch an online learning program entitled “Parkinson’s Disease Psychosis: A Learning Destination for Care Partners and Patients,” available on Medscape’s patient portal, WebMD Education.

Parkinson’s Foundation Designates Three Centers of Excellence in Parkinson’s Care: Global Network Expands to 45 Parkinson’s Centers
Tuesday, July 24, 2018

MIAMI & NEW YORK CITY — July 24, 2018 — The Parkinson’s Foundation today announced the addition of three new Centers of Excellence to its global network: Cleveland Clinic; Medical University of South Carolina; and University of Iowa Hospitals and Clinics.

Parkinson’s Foundation Funds $450,000 for Local Parkinson’s Programs in Seven Cities Across the Country
Monday, July 23, 2018

NEW YORK & MIAMI — July 23, 2018 — The Parkinson's Foundation today announced it will fund nearly $450,000 to local community grants in seven cities that hosted the Foundation's annual fundraiser, Moving Day, A Walk for Parkinson's, in 2017. These grants will further the health, wellness and education of people with Parkinson's disease (PD).

In Memory of Robert Traurig
Wednesday, July 18, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member Robert (Bob) Traurig. From 2004 to 2015, he was a member of the Foundation’s board of directors. Bob is survived by his wife Jacqueline, his daughters Madeline Sackel and Wendy Traurig.

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.